Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by JLGeminion Sep 15, 2010 7:36pm

254 Views

Post# 17453452

RE: RE: Pfizer and Questions for Pericles

Cartach, I understand your point. The application of Reolysin has vast potential. I do not want to sustain a discussion of a memory challenge when the critical issue facing the Discussion Board is the unrealistic market cap valation of Oncolytics. Let's let the rally run. I think a market cap valuation is of $1/2 billion as of today is a conservative estimate for the point that you raised.

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages